EPIC ORDER CODE LAB5264 Ehrlichia/Anaplasma, Molecular Detection, PCR, Blood
Additional Codes
SQ: EHRLM
MAYO: EPCRB
Specimen Required
Container/Tube: Lavender top (EDTA)
Specimen Volume: 1 mL
Collection Instructions: Send whole blood specimen in original tube. Do not aliquot.
Useful For
Evaluating patients suspected of acute anaplasmosis or ehrlichiosis
This test should not be used for screening asymptomatic individuals.
Method Name
Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization
Reporting Name
Ehrlichia/Anaplasma, PCR, BSpecimen Type
Whole Blood EDTASpecimen Minimum Volume
0.3 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Whole Blood EDTA | Refrigerated | 7 days |
Reject Due To
Gross hemolysis | OK |
Gross lipemia | Reject |
Clinical Information
Ehrlichiosis and anaplasmosis are a group of emerging zoonotic tick-borne infections caused by Ehrlichia and Anaplasma species, respectively. These obligate intracellular, gram-negative rickettsial organisms infect leukocytes and cause a potentially serious febrile illness in humans.
Human granulocytic anaplasmosis (HGA), formerly known as human granulocytic ehrlichiosis, is caused by Anaplasma phagocytophilum, which is transmitted through the bite of an infected Ixodes species tick. The epidemiology of this infection in the United States is very much like that of Lyme disease (caused by Borrelia burgdorferi) and babesiosis (caused primarily by Babesia microti), which all have the same tick vector. HGA is most prevalent in the upper Midwest and in other areas of the United States that are endemic for Lyme disease.
Human monocytic ehrlichiosis (HME) is caused by Ehrlichia chaffeensis, which is transmitted by the Lone Star tick, Amblyomma americanum. Most cases of HME have been reported from the Southeastern and South-Central regions of the United States. Ehrlichia ewingii, the known cause of canine granulocytic ehrlichiosis, can occasionally cause an HME-like illness in humans. Clinical features and laboratory abnormalities are similar to those of E chaffeensis infection, and antibodies to E ewingii cross-react with current serologic assays for detection of antibodies to E chaffeensis.
Most recently, Mayo Clinic Laboratories detected a new species of Ehrlichia in patients with exposure to ticks in Wisconsin and Minnesota. This organism is most closely related to Ehrlichia muris and therefore, has been referred to as the E muris-like agent or EMLA. The name Ehrlichia muris eauclairensis has recently been proposed after the city in which the first case was described. E muris eauclairensis causes a similar disease to ehrlichiosis due to E chaffeensis and E ewingii and may cause more severe disease in immunocompromised hosts.
Most cases of anaplasmosis and ehrlichiosis are subclinical or mild, but infection can be severe and life-threatening in some individuals. Fever, fatigue, malaise, headache, and other "flu-like" symptoms, including myalgias, arthralgias, and nausea, occur most commonly. Central nervous system involvement can result in seizures and coma.
Diagnosis may be difficult since the patient's clinical course is often mild and nonspecific. This symptom complex is easily confused with other illnesses (such as influenza) or other tick-borne zoonoses (such as Lyme disease, babesiosis, and Rocky Mountain spotted fever). Clues to the diagnosis of ehrlichiosis in an acutely febrile patient after tick exposure include laboratory findings of leukopenia or thrombocytopenia and elevated serum aminotransferase levels. However, while these abnormal laboratory findings are frequently seen, they are not specific. Rarely, intra-granulocytic or monocytic morulae may be observed on peripheral blood smear, but this is not a reliable means of diagnosing cases of human ehrlichiosis or anaplasmosis.
Definitive diagnosis is usually accomplished through polymerase chain reaction (PCR) and serologic methods. Serologic testing is done primarily for confirmatory purposes by demonstrating a 4-fold rise or fall in specific antibody titers to Ehrlichia species or Anaplasma antigens. There is not currently a commercially available specific serologic test for E muris eauclairensis, but cross-reactivity with the other Ehrlichia species by serology may be detected.
PCR techniques allow direct detection of pathogen-specific DNA from patients' whole blood and is the preferred method for detection during the acute phase of illness. The Mayo Clinic PCR assay is capable of detecting and differentiating A phagocytophilum, E chaffeensis, E ewingii, and E muris eauclairensis.
It is important to note that concurrent infection with A phagocytophilum, Borrelia burgdorferi, and Babesia microti is not uncommon, as these organisms share the same Ixodes tick vector. Additional testing for these pathogens may be indicated.
Reference Values
Negative
Reference values apply to all ages.
Interpretation
Positive results indicate presence of specific DNA from Ehrlichia chaffeensis, Ehrlichia ewingii, Ehrlichia muris eauclairensis organism, or Anaplasma phagocytophilum and support the diagnosis of ehrlichiosis or anaplasmosis.
Negative results indicate absence of detectable DNA from any of these 4 pathogens in specimens but do not exclude the presence of these organisms or active or recent disease.
Since DNA of E ewingii is indistinguishable from that of Ehrlichia canis by this rapid polymerase chain reaction assay, a positive result for E ewingii/canis indicates the presence of DNA from either of these 2 organisms.
Clinical Reference
1. Bakken JS, Dunler JS: Human granulocytic ehrlichiosis. Clin Infect Dis. 2000 Aug;31(2):554-560
2. Dumler JS, Bakken JS: Human ehrlichioses: newly recognized infections transmitted by ticks. Ann Rev Med. 1998;49:201-213
3. Krause PJ, McKay K, Thompson CA, et al: Disease-specific diagnosis of coinfecting tickborne zoonoses: babesiosis, human granulocytic ehrlichiosis, and Lyme disease. Clin Infect Dis. 2002 May 1;34(9):1184-1191
4. McQuiston JH, Paddock CD, Holman RC, Childs JE: The human ehrlichioses in the United States. Emerg Infect Dis. 1999 Sept-Oct;5(5):635-642
5. Pritt BS, Sloan LM, Johnson DK, et al: Emergence of a new pathogenic Ehrlichia species, Wisconsin and Minnesota, 2009. N Engl J Med. 2011 Aug 4;365(5):422-429
6. Johnson DKH, Schiffman EK, Davis JP, et al: Human infection with Ehrlichia muris-like pathogen, United States, 2007-2013. Emerg Infect Dis. 2015 Oct; 21(10):1794-1799
Method Description
Nucleic acid is extracted from the pathogens in blood using the automated MagNA Pure LC system. The extract is then transferred to a 96-well Lightcycler 480 dish for amplification. The LightCycler 480 is an automated instrument that amplifies and monitors the development of target nucleic acid (amplicon) after each cycle of polymerase chain reaction (PCR). The DNA target for PCR assay is groEL, the open reading frame gene segment of the heat-shock protein operon (groEL), which is present at a frequency of 1 copy per organism in pathogenic species of Anaplasma and Ehrlichia. A specific base pair DNA target sequence is amplified by PCR. The detection of amplicon is based on fluorescence resonance energy transfer, which utilizes a hybridization probe with a donor fluorophore, fluorescein, at the 3' end and a second hybridization probe with an acceptor fluorophore, LC-Red 640, at the 5' end. When the target amplicon is present, the LC-Red 640 emits a measurable and quantifiable light signal at a specific wavelength. Presence of the specific organism nucleic acid may be confirmed by performing a melting curve analysis of the amplicon. Using features of the melting curve analysis, the assay primers and specific hybridization probes are able to detect and differentiate among Anaplasma phagocytophilum, Ehrlichiosis chaffeensis, Ehrlichia muris eauclairensis, and Ehrlichia ewingii/canis. Due to close proximity of the melting curves of Ehrlichia ewingii and Ehrlichia canis, this assay cannot distinguish between these 2 organisms.(Unpublished Mayo method)
Day(s) Performed
Monday through Saturday
Report Available
Same day/1 to 4 daysSpecimen Retention Time
1 weekPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
87468
87484
87798 x 2
87999 ( if appropriate for government payers)
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
EPCRB | Ehrlichia/Anaplasma, PCR, B | 87548-4 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
618323 | Anaplasma phagocytophilum | 87558-3 |
618324 | Ehrlichia chaffeensis | 87559-1 |
618325 | Ehrlichia ewingii/canis | 87560-9 |
618326 | Ehrlichia muris eauclairensis | 87561-7 |
Forms
If not ordering electronically, complete, print, and send Microbiology Test Request (T244) with the specimen.